Provided are methods of treating subjects having, or at risk of having, heart disease, cardiovascular disease, coronary artery disease, cerebrovascular disease, acute or chronic renal disease, and/or symptoms thereof with certain therapeutically effective doses and dosing regimens comprising an isolated and purified lecithin-cholesterol acyltransferase (LCAT) enzyme, in particular, a recombinant human LCAT (rhLCAT) enzyme, e.g., MEDI6012. The methods involving administration of the described doses of rhLCAT increase serum levels of high density lipoprotein (HDL) and apolipoprotein A1 (apoA1) and decrease, or do not appreciably increase, serum levels of apolipoprotein B in the treated subjects, thus affording treatment of heart disease, heart-related diseases and coronary artery disease. The methods involving the described dosing regimens and doses of rhLCAT or MEDI6012 administered to a subject further provide cardio-, myocardio- and cardiovascular protection for the subject, including protection against ischemic stroke, myocardiocyte apoptosis, atherosclerosis progression and the like.本發明提供用某些治療有效劑量及給藥方案治療患有以下疾病或具有罹患以下疾病之風險的個體的方法：心臟病、心血管疾病、冠狀動脈疾病、腦血管疾病、急性或慢性腎病及/或其症狀，其包含經分離及純化之卵磷脂-膽固醇醯基轉移酶(LCAT)酶，特別是重組人類LCAT (rhLCAT)酶，例如MEDI6012。涉及投與所描述劑量之rhLCAT的方法增加經治療個體中之高密度脂蛋白(HDL)及脂蛋白元A1 (apoA1)之血清含量且減小或不會明顯地增加脂蛋白元B之血清含量，從而提供對心臟病、心臟相關疾病及冠狀動脈疾病之治療。涉及向個體投與rhLCAT或MEDI6012之所描述之給藥方案及劑量的方法進一步為該個體提供心臟、心肌及心血管保護，包括對抗缺血性中風、心肌細胞凋亡、動脈粥樣硬化進展及其類似疾病的保護。
